Transparency in Medicines Regulatory Affairs - Reclaiming Missed Opportunities

Y A Vawda, A Gray


Transparency is a salutary value in our constitutional architecture. It has also been described as a necessary element in promoting accountability in the regulatory aspects of essential medicines. Despite its several incarnations, the Medicines and Related Substances Act (Medicines Act) retains a provision headed 'Preservation of secrecy' (section 34). This contributionseeks to evaluate section 34 in the context of transparency and ascertain whether it is in conflict with other legislation pertaining to the promotion of access to information and, in particular, whether it is consistent with the Constitution of the Republic of South Africa.

Authors' affiliations

Y A Vawda, School of Law, College of Law and Management Studies, University of KwaZulu-Natal, Durban, South Africa

A Gray, Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa

Full Text

PDF (70KB)

Cite this article

South African Journal of Bioethics and Law 2017;10(2):69-74. DOI:10.7196/SAJBL.2017.v10i2.00607

Article History

Date submitted: 2017-12-20
Date published: 2017-12-20

Article Views

Abstract views: 2450
Full text views: 1617

Comments on this article

*Read our policy for posting comments here
View all comments